Form 8-K - Current report:
SEC Accession No. 0001193125-24-194177
Filing Date
2024-08-06
Accepted
2024-08-05 21:21:29
Documents
13
Period of Report
2024-08-05
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d874511d8k.htm   iXBRL 8-K 26517
  Complete submission text file 0001193125-24-194177.txt   151996

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ikt-20240805.xsd EX-101.SCH 2855
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ikt-20240805_lab.xml EX-101.LAB 18736
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ikt-20240805_pre.xml EX-101.PRE 11711
15 EXTRACTED XBRL INSTANCE DOCUMENT d874511d8k_htm.xml XML 3768
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39676 | Film No.: 241176782
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)